Clinical Trials Now Enrolling


ABEMACICLIB IN COMBINATION WITH LY3214996 FOR RECURRENT GLIOBLASTOMA 

A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma participants scheduled for resection to evaluate central nervous system (CNS) penetration 


Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT04391595 to view inclusion criteria and additional study details.


INFIGRATINIB FOR RECURRENT GLIOBLASTOMA

A Phase 0 study of infigratinib in recurrent high-grade glioma participants with an FGFR gene fusion scheduled for resection to evaluate central nervous system (CNS) penetration with PK triggered expansion cohort


Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT04424966 to view inclusion criteria and additional study details.


RIBOCICLIB FOR RECURRENT GLIOBLASTOMA

A Phase 0/2 Study of Ribociclib in Preoperative Rb-Positive Recurrent High-Grade Glioma Patients Scheduled for Resection


Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT02933736  to view inclusion criteria and additional study details.


RIBOCICLIB FOR RECURRENT MENINGIOMA

A Phase 0/2 Study of Ribociclib in Preoperative Rb-Positive Recurrent High-Grade Meningioma Patients Scheduled for Resection


Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT02933736  to view inclusion criteria and additional study details.


RIBOCICLIB PLUS EVEROLIMUS FOR RECURRENT GLIOBLASTOMA

A Phase 0/2 Study of Ribociclib in Combination With Everolimus in Preoperative Rb-Intact Recurrent High-Grade Glioma Patients Scheduled for Resection


Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT03834740  to view inclusion criteria and additional study details.


This list was last updated 08/26/2020


NEW DIAGNOSis?

Ivy Phase 0 clinical trials are currently available for patients whose tumors have recurred and require surgery. If you are a newly-diagnosed brain tumor patient, please feel free to contact us for additional information on current standard-of-care treatments.  In the event that your tumor does recur, we will have options. Talk to an Ivy Navigator today to discuss establishing a proactive treatment plan.